The abnormal accumulation of immune plasma cells in the lungs — and their subsequent generation of damaging antibodies — may be a key driver of idiopathic pulmonary fibrosis (IPF), according to new research by scientists from Rutgers Health. The researchers found that antibody-producing plasma cells first accumulated in the…
News
Blocking Piezo2, a protein receptor that senses mechanical forces in tissues — ones such as stress, strain, and stiffness — may be a new way to slow the progression of idiopathic pulmonary fibrosis (IPF), according to a study by U.S. researchers. The scientists, who noted that this was the…
Basal stem cells taken from the upper part of a patient’s respiratory tract can be expanded in the lab and then transplanted back into their lungs to treat idiopathic pulmonary fibrosis (IPF), according to a recent study. “Our clinical observations herein show that [basal cells] infusion is able to…
Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due to safety issues. The BEACON-IPF (NCT06097260)Â trial was assessing whether once-daily doses of bexotegrast (160 mg or 320 mg) could improve lung function in about 360 IPF patients, ages 40…
The National Organization for Rare Disorders (NORD) is seeking participants for its survey-based study Living Rare, which aims to better understand the real-world lived experiences of people in the U.S. with rare diseases. Living Rare, the first large-scale study of its kind in the U.S., seeks to capture the…
Enrollment is now complete in a Phase 2b clinical trial, dubbed CORAL, that’s testing nalbuphine extended-release (ER) tablets — planned to be marketed as Haduvio — in people with idiopathic pulmonary fibrosis (IPF) who experience chronic cough. That achievement was announced by Trevi Therapeutics, the U.S. company…
A Phase 1 clinical trial testing Cereno Scientific’s candidate therapy for idiopathic pulmonary fibrosis (IPF) in healthy volunteers has moved to its final part, the company has announced. This first-in-human, open-label trial is testing CS014 at single and multiple ascending doses in about 48 participants. The part that evaluated…
A protein called Runx2 contributes to the abnormal activity of lung cells that drive pulmonary fibrosis, a new study shows, suggesting that inhibiting this protein may be an effective strategy for treating the disease. “Our study suggests Runx2 is a potential therapeutic target for preventing or treating pulmonary…
Nerandomilast, an oral treatment being developed by Boehringer Ingelheim, bested a placebo at preserving lung function in adults with progressive pulmonary fibrosis in a Phase 3 study, according to top-line data announced by the company. With those results, nerandomilast met the primary endpoint, or goal, of the study,…
Low total cholesterol levels are linked to a higher risk of death among people with idiopathic pulmonary fibrosis, a new study from China with more than three years of follow-up data found. “We conducted a long-term follow-up study in patients with IPF and observed that lower [total cholesterol] levels…
